We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
โข Company will move forward with trial sites across North America Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (โAmylyxโ or the โCompanyโ) today announced that the U.S. Food and Drug...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (โAmylyxโ or the โCompanyโ) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (โAmylyxโ or the โCompanyโ) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are...
- Dan Monahan will lead the commercialization strategy across Amylyxโ product portfolio, beginning with avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1619 | 5.22258064516 | 3.1 | 3.665 | 3.02 | 1113719 | 3.38981788 | CS |
4 | -0.8281 | -20.2469437653 | 4.09 | 4.18 | 3.02 | 775951 | 3.59081345 | CS |
12 | -2.1581 | -39.8173431734 | 5.42 | 7.27 | 3.02 | 1057278 | 4.96489222 | CS |
26 | 1.2419 | 61.4801980198 | 2.02 | 7.27 | 1.76 | 1168398 | 3.84967658 | CS |
52 | -11.6081 | -78.0638870208 | 14.87 | 19.9488 | 1.575 | 1839093 | 4.32625957 | CS |
156 | -16.8581 | -83.7877733598 | 20.12 | 41.9297 | 1.575 | 1337978 | 14.635489 | CS |
260 | -17.7381 | -84.4671428571 | 21 | 41.9297 | 1.575 | 1329007 | 14.65917485 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions